Allspring Global Investments Holdings LLC Purchases 16,421 Shares of Repligen Corporation (NASDAQ:RGEN)

Allspring Global Investments Holdings LLC boosted its stake in Repligen Corporation (NASDAQ:RGEN - Free Report) by 3.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 473,486 shares of the biotechnology company's stock after acquiring an additional 16,421 shares during the period. Allspring Global Investments Holdings LLC owned 0.84% of Repligen worth $60,843,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in RGEN. Signaturefd LLC boosted its stake in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new stake in Repligen during the 4th quarter valued at approximately $29,000. Raiffeisen Bank International AG purchased a new position in shares of Repligen during the 4th quarter worth approximately $29,000. Itau Unibanco Holding S.A. bought a new position in shares of Repligen in the 4th quarter worth approximately $40,000. Finally, Global Retirement Partners LLC raised its position in shares of Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 129 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on RGEN shares. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price target on shares of Repligen in a research note on Monday, May 5th. Evercore ISI initiated coverage on shares of Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 target price on the stock. Wall Street Zen lowered shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday. Barclays initiated coverage on Repligen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 target price on the stock. Finally, Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a report on Tuesday, April 29th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Repligen presently has an average rating of "Moderate Buy" and a consensus target price of $172.83.

Repligen Stock Up 0.3%

Shares of RGEN stock traded up $0.40 during mid-day trading on Thursday, hitting $127.36. The company's stock had a trading volume of 208,766 shares, compared to its average volume of 727,035. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. Repligen Corporation has a 52-week low of $102.97 and a 52-week high of $182.52. The stock has a market cap of $7.16 billion, a price-to-earnings ratio of -283.02, a PEG ratio of 3.62 and a beta of 1.11. The business has a 50-day moving average price of $127.41 and a 200 day moving average price of $140.41.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. The business had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. Repligen's revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.28 EPS. Research analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.